Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

DragonAlgo Mar. 5 at 9:31 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-03-13 | Strike: $240.00 | Type: CALL Option Plan (premium): Entry: $3.35 Stop: $2.41 TP1: $4.35 TP2: $5.69 TP3: $8.04 Risk preset by model constraints. 🔗 https://dragonalgo.com

0 · Reply

atulshubham Mar. 5 at 8:58 PM

$JNJ https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-tecvayli-plus-darzalex-faspro-for-relapsed-refractory-multiple-myeloma-offering-a-potential-new-standard-of-care-as-early-as-second-line

0 · Reply

StockNews_Live Mar. 5 at 8:56 PM

$JNJ Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adults …

0 · Reply

Suite510 Mar. 5 at 8:28 PM

$JNJ $KVUE $SPX $SPY Good job Junk n Junk you sold at the top of the market to pay your Talc Lawyers and your future 30B verdict 🤣🍷

0 · Reply

PittsburghTrader Mar. 5 at 7:56 PM

$JNJ incredible pullback… legging into bullish swing … way too much here

0 · Reply

itsfloridaking Mar. 5 at 4:12 PM

$IWM $JNJ $O $PFE Bannnnng!!!! +1723%

0 · Reply

itsfloridaking Mar. 5 at 4:11 PM

$IWM $JNJ $O $PFE Who’s your daddy 😂🫵

0 · Reply

PittsburghTrader Mar. 5 at 3:43 PM

$MRK ok, both $MRK & $JNJ pullback today look overdone given overall $SPY not down much… taking bullish swing bets here

0 · Reply

sideload Mar. 5 at 3:00 PM

$ABT $BSX $GEHC $ICU $JNJ

1 · Reply

Godsgrace2025 Mar. 5 at 2:49 PM

$QQQ $JNJ $AAPL $MLTX God is Good 🙏

1 · Reply

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 10 hours ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 1 day ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 2:02 PM EST - 2 days ago

Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 1:18 PM EST - 2 days ago

Wasatch Global Value Fund Q4 2025 Performance Review

BABA C T VICI

Mar 3, 2026, 8:03 AM EST - 2 days ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 2, 2026, 4:30 PM EST - 3 days ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Feb 27, 2026, 12:21 PM EST - 6 days ago

Best Dividend Aristocrats For March 2026

ABBV ABT ADM ADP AFL ALB AMCR

Feb 26, 2026, 5:34 PM EST - 7 days ago

2 Dividend Kings That Could Easily Keep The Growth Streak Alive

AWR DOV GPC PG

Feb 26, 2026, 2:30 PM EST - 7 days ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 9 days ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 10 days ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 10 days ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 10 days ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 12 days ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:30 PM EST - 14 days ago

Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)

Feb 19, 2026, 5:00 PM EST - 14 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 14 days ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 14 days ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 9:15 AM EST - 14 days ago

2 High-Yield CEFs To Enhance Your Retirement Income

AMLP ASGI BIZD BTI MO SCHD T

Feb 18, 2026, 10:44 AM EST - 15 days ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 15 days ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 15 days ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 15 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 16 days ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 6:23 AM EST - 16 days ago

Dividend Income: Lanny's December 2025 Summary

ADM AFL EMR GWW IBM LYB MCD

Feb 13, 2026, 4:19 PM EST - 20 days ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:18 PM EST - 20 days ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 2:43 PM EST - 20 days ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 7:00 AM EST - 20 days ago

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 11, 2026, 2:23 PM EST - 22 days ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 9, 2026, 4:16 PM EST - 24 days ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 6, 2026, 7:00 PM EST - 27 days ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 5, 2026, 1:00 PM EST - 4 weeks ago

The Big 3: JNJ, XOM, KO

XOM KO

Feb 4, 2026, 1:37 PM EST - 4 weeks ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

Feb 3, 2026, 8:47 AM EST - 4 weeks ago

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 3:00 AM EST - 4 weeks ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 2, 2026, 4:34 PM EST - 4 weeks ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 1, 2026, 10:35 AM EST - 4 weeks ago

Ariel Focus Fund Q4 2025 Portfolio Review

ADT AMG B FISV MOS ORCL

Jan 30, 2026, 2:43 PM EST - 4 weeks ago

Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

Jan 30, 2026, 7:19 AM EST - 4 weeks ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 29, 2026, 6:32 PM EST - 5 weeks ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 12:42 PM EST - 5 weeks ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

Jan 28, 2026, 9:38 AM EST - 5 weeks ago

Johnson & Johnson: Strong Momentum Heading Into 2026

Jan 27, 2026, 3:49 PM EST - 5 weeks ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Jan 27, 2026, 8:00 AM EST - 5 weeks ago

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

Jan 25, 2026, 10:11 PM EST - 5 weeks ago

Best Dividend Kings: January 2026

ABBV ABM ABT ADM ADP AWR BDX

Jan 22, 2026, 12:15 AM EST - 6 weeks ago

Johnson & Johnson is doing 'great things for patients,' CFO says

Jan 21, 2026, 11:20 PM EST - 6 weeks ago

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Jan 21, 2026, 6:45 PM EST - 6 weeks ago

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

DragonAlgo Mar. 5 at 9:31 PM

0 · Reply

atulshubham Mar. 5 at 8:58 PM

0 · Reply

StockNews_Live Mar. 5 at 8:56 PM

0 · Reply

Suite510 Mar. 5 at 8:28 PM

$JNJ $KVUE $SPX $SPY Good job Junk n Junk you sold at the top of the market to pay your Talc Lawyers and your future 30B verdict 🤣🍷

0 · Reply

PittsburghTrader Mar. 5 at 7:56 PM

$JNJ incredible pullback… legging into bullish swing … way too much here

0 · Reply

itsfloridaking Mar. 5 at 4:12 PM

$IWM $JNJ $O $PFE Bannnnng!!!! +1723%

0 · Reply

itsfloridaking Mar. 5 at 4:11 PM

$IWM $JNJ $O $PFE Who’s your daddy 😂🫵

0 · Reply

PittsburghTrader Mar. 5 at 3:43 PM

$MRK ok, both $MRK & $JNJ pullback today look overdone given overall $SPY not down much… taking bullish swing bets here

0 · Reply

sideload Mar. 5 at 3:00 PM

$ABT $BSX $GEHC $ICU $JNJ

1 · Reply

Godsgrace2025 Mar. 5 at 2:49 PM

$QQQ $JNJ $AAPL $MLTX God is Good 🙏

1 · Reply

Nasfact Mar. 5 at 2:25 PM

$SLS what stood out to me doing some digging was $PFE and $JNJ At JNJ Sellas would fill a big gap in AML and peptide based immuo oncology as they do not have assets there... At Pfizer we would have some portfolio crossings and the strategic advantage would be not as additive... Both have good cash and would be good competitors in bidding wars...

1 · Reply

DragonAlgo Mar. 5 at 12:15 AM

🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-03-13 | Strike: $245.00 | Type: PUT Option Plan (premium): Entry: $3.15 Stop: $2.27 TP1: $4.09 TP2: $5.35 TP3: $7.56 🔗 https://dragonalgo.com

0 · Reply

Deeznutsswapmeet Mar. 4 at 10:01 PM

$IWM $JNJ $O $PFE Bombs away? Great call, any other prophecies fortune teller?

2 · Reply

itsfloridaking Mar. 4 at 3:06 PM

$IWM $JNJ $O $PFE Bombs away 😂😂😂😂🔥🫦

0 · Reply

clan Mar. 4 at 1:51 PM

$NVS $MRK $JNJ 🚨 Did you know?!?! INHALABLE ultra rapid-acting mealtime INSULIN for diabetics ! ! ! For the good of all Mannkind! 😲 Wow! 😁

0 · Reply

DragonAlgo Mar. 4 at 5:39 AM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-03-13 | Strike: $245.00 | Type: CALL Option Plan (premium): Entry: $5.07 Stop: $3.65 TP1: $6.60 TP2: $8.63 TP3: $12.18 🔗 https://dragonalgo.com

0 · Reply

itsfloridaking Mar. 3 at 9:41 PM

SHORT the following $IWM $PFE $JNJ $O 🏴‍☠️

2 · Reply

Godsgrace2025 Mar. 3 at 8:53 PM

$INTT $QQQ $JNJ $MLTX God is Good

0 · Reply

IN0V8 Mar. 3 at 8:48 PM

$JNJ BofA Global Research raises price objective to $253 from $227

0 · Reply

StockNews_Live Mar. 3 at 1:03 PM

$JNJ Johnson & Johnson therapy nipocalimab has been granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE). This designation is intended to expedite the development and review of nip…

0 · Reply

DragonAlgo Mar. 3 at 12:51 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-03-06 | Strike: $247.50 | Type: CALL Option Plan (premium): Entry: $3.12 Stop: $2.25 TP1: $4.06 TP2: $5.30 TP3: $7.49 🔗 https://dragonalgo.com

0 · Reply

Suite510 Mar. 3 at 11:56 AM

$JNJ $KVUE $SPX $SPY Whoops the slide 🛝 begins 😂⛽️

2 · Reply

Market Cap	591.15B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.85
Forward PE	21.38
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	9,375,400
Avg Vol	8,706,040
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	23%
Beta	0.34
Analysts	Strong Sell
Price Target	$237.92